{"organizations": [], "uuid": "dc11bbef837af48b34d4770cbaaf5e5a2b674587", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180119.html", "section_title": "Archive News &amp; Video for Friday, 19 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biotest-all-conditions-met-for-cre/brief-biotest-all-conditions-met-for-creat-takeover-of-biotest-idUSASM000IB2", "country": "US", "domain_rank": 408, "title": "BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.626, "site_type": "news", "published": "2018-01-20T01:12:00.000+02:00", "replies_count": 0, "uuid": "dc11bbef837af48b34d4770cbaaf5e5a2b674587"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biotest-all-conditions-met-for-cre/brief-biotest-all-conditions-met-for-creat-takeover-of-biotest-idUSASM000IB2", "ord_in_thread": 0, "title": "BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biotest ag", "sentiment": "negative"}, {"name": "cfius", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - BIOTEST AG:\n* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST\n* FOREIGN TRADE APPROVAL HAS BEEN GIVEN BY U.S. COMMITTEE ON FOREIGN INVESTMENT IN UNITED STATES (CFIUS)\n* LAST REMAINING CONDITION HAS BEEN MET FOR TAKEOVER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG\n* THUS UNSOLICITED TAKEOVER BID ANNOUNCED ON MAY 18, 2017 FOR SHARES OF BIOTEST AG BECOMES EFFECTIVE\n* IN CONNECTION WITH APPROVAL, BIOTEST HAS SIGNED AN AGREEMENT FOR SALE OF ITS U.S. COMPANIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-20T01:12:00.000+02:00", "crawled": "2018-01-20T17:28:57.135+02:00", "highlightTitle": ""}